This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
For patients with moderately to severely active ulcerative colitis, onset of action is an important consideration when choosing appropriate therapy to provide timely symptomatic relief1
Based on post-hoc analyses of daily patient diary data from the OCTAVE induction studies:
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
Learn more about the XELJANZ safety profile
Learn about dosing in UC
Find out more about how XELJANZ works
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023